DataM Blog

DataM resources that are widely useful for your reference. We have curated special links for you to browse through

blog categories

Food and Beverage Healthcare Agriculture Chemicals and Materials Information & Communications Technology Electronics & Semiconductor Energy and Power Automotive and Aviation Consumer Goods Others

Actinium-225 Supply Chain Expansion Signals the Next Phase of Precision Oncology

Growing demand for targeted alpha therapy is driving major investments in Actinium-225 production capacity. New isotope manufacturing facilities are strengthening the radiopharmaceutical supply chain and supporting the future of precision cancer treatments.

July 21, 2026

Top MASH Drug Companies in 2026: Madrigal, Novo Nordisk, Boehringer Ingelheim, Akero, and 89bio Shape the Treatment Landscape

The MASH treatment landscape has entered a new commercial phase following the approval of the first liver-directed therapy. This competitive analysis examines Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Akero, 89bio, Inventiva and other companies competing through THR-β, GLP-1, FGF21 and fibrosis-focused treatment strategies.

July 13, 2026

Top Companies Driving Innovation in Medical Biosensors Industry

The medical biosensors industry is rapidly transforming modern healthcare through advanced diagnostic and monitoring technologies that enable real-time, accurate, and non-invasive health tracking. As demand for wearable devices, point-of-care diagnostics, and continuous health monitoring continues to rise, several leading global companies are driving innovation and shaping the future of the sector. This article explores the top companies in the medical biosensors industry, highlighting their contributions, technologies, and role in advancing personalized healthcare and next-generation medical solutions.

July 6, 2026

Top Companies Advancing Nanotechnology in Drug Delivery Systems

Nanotechnology in drug delivery is transforming modern healthcare by enabling targeted, controlled, and efficient delivery of therapeutic agents at the molecular level. Leading pharmaceutical and biotechnology companies are investing heavily in nanomedicine to improve treatment outcomes, reduce side effects, and enhance precision medicine approaches. This blog highlights key companies driving innovation in nanotechnology-based drug delivery systems across global healthcare and life sciences industries.

June 26, 2026

Can Healthcare Robotics Solve the Hospital Workforce Crisis? Market Trends, Technologies, and Future Opportunities

Healthcare systems worldwide face an unprecedented workforce shortage driven by aging populations, rising patient volumes, clinician burnout, and increasing operational costs. To address these challenges, hospitals are rapidly adopting healthcare robotics systems that automate repetitive tasks, improve surgical precision, enhance rehabilitation outcomes, and optimize hospital logistics. From robotic-assisted surgery and pharmacy automation to autonomous hospital delivery robots and AI-powered rehabilitation platforms, healthcare robotics is transforming the future of care delivery. As healthcare providers seek scalable solutions to workforce constraints, the global healthcare robotics systems market is emerging as one of the fastest-growing segments within healthcare technology. According to DataM Intelligence analysis, continued investments in hospital automation, minimally invasive surgery, and intelligent healthcare infrastructure are expected to accelerate market growth through 2035.

June 25, 2026

Which Neurological Rare Disease Treatment Brands Stand Out for Competitive Pricing?

The global rare neurological disease drugs market is undergoing rapid transformation driven by precision medicine, orphan drug incentives, and escalating treatment costs. As demand rises for therapies targeting conditions such as spinal muscular atrophy (SMA), multiple sclerosis-related rare syndromes, Huntington’s disease, and lysosomal storage disorders, pricing competitiveness has become a decisive factor for payers, healthcare providers, and investors. This article analyzes leading pharmaceutical brands, their pricing strategies, and how competitive positioning is reshaping access, adoption, and long-term market share in the rare neurological disease treatment landscape.

June 19, 2026